148 related articles for article (PubMed ID: 34619749)
1. [First appropriate implantable defibrillator shocks in patients with Chagasic heart disease].
García-Chamorro LG; Zaidel EJ; Gheco L; Oliva MA; de-la-Vega A; Orosco A; Armentano J; Sosa-Liprandi Á
Arch Cardiol Mex; 2022 Jul; 92(3):342-348. PubMed ID: 34619749
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease.
Waldmann V; Marquié C; Bessière F; Perrot D; Anselme F; Badenco N; Barra S; Bertaux G; Blangy H; Bordachar P; Boveda S; Chauvin M; Clémenty N; Clerici G; Combes N; Defaye P; Deharo JC; Durand P; Duthoit G; Eschalier R; Fauchier L; Garcia R; Geoffroy O; Gitenay E; Gourraud JB; Guenancia C; Iserin L; Jacon P; Jesel-Morel L; Kerkouri F; Klug D; Koutbi L; Labombarda F; Ladouceur M; Laurent G; Leclercq C; Maille B; Maltret A; Massoulié G; Mondoly P; Ninni S; Ollitrault P; Pasquié JL; Pierre B; Pujadas P; Champ-Rigot L; Sacher F; Sadoul N; Schatz A; Winum P; Milliez PU; Probst V; Marijon E
J Am Coll Cardiol; 2023 Aug; 82(7):590-599. PubMed ID: 37558371
[TBL] [Abstract][Full Text] [Related]
4. Electrocardiographic Markers of Appropriate Implantable Cardioverter-Defibrillator Therapy in Young People with Congenital Heart Diseases.
Benítez Ramos DB; Cabrera Ortega M; Castro Hevia J; Dorantes Sánchez M; Alemán Fernández AA; Castañeda Chirino O; Cruz Cardentey M; Martínez López F; Falcón Rodríguez R
Pediatr Cardiol; 2017 Dec; 38(8):1663-1671. PubMed ID: 28871362
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease.
Rassi FM; Minohara L; Rassi A; Correia LCL; Marin-Neto JA; Rassi A; da Silva Menezes A
JACC Clin Electrophysiol; 2019 Oct; 5(10):1213-1223. PubMed ID: 31648747
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
[TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter/defibrillator interventions in primary prevention: do current implantation criteria really predict ICD interventions?
Cools T; Rossenbacker T; Floré V; Nuyens D; Heidbochel H; Willems R
Acta Cardiol; 2011 Apr; 66(2):145-51. PubMed ID: 21591571
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of Chagas heart disease patients receiving an implantable cardioverter-defibrillator for secondary prevention.
Pavão MLRC; Arfelli E; Scorzoni-Filho A; Rassi A; Pazin-Filho A; Pavão RB; Marin-Neto JA; Schmidt A
Pacing Clin Electrophysiol; 2018 Jun; 41(6):583-588. PubMed ID: 29578582
[TBL] [Abstract][Full Text] [Related]
10. Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators.
Seegers J; Conen D; Jung K; Bergau L; Dorenkamp M; Lüthje L; Sohns C; Sossalla ST; Fischer TH; Hasenfuss G; Friede T; Zabel M
Europace; 2016 Aug; 18(8):1194-202. PubMed ID: 26622054
[TBL] [Abstract][Full Text] [Related]
11. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register.
Weeke P; Johansen JB; Jørgensen OD; Nielsen JC; Møller M; Videbæk R; Højgaard MV; Riahi S; Jacobsen PK
Europace; 2013 Aug; 15(8):1150-7. PubMed ID: 23407630
[TBL] [Abstract][Full Text] [Related]
12. Predictors of implantable cardioverter defibrillator shocks during the first year.
Dougherty CM; Hunziker J
J Cardiovasc Nurs; 2009; 24(1):21-8; quiz 29-30. PubMed ID: 19114797
[TBL] [Abstract][Full Text] [Related]
13. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Subcutaneous Implantable Cardioverter-Defibrillator Shocks and Prognostic Impact in Patients With Structural Heart Disease.
Ninni S; Echivard M; Marquié C; Ortmans S; Labreuche J; Drumez E; Lemaire J; Cuvillier A; Arnaud M; Potelle C; Gouraud JB; Andorin A; Blangy H; Sadoul N; Probst V; Klug D
Can J Cardiol; 2021 Mar; 37(3):400-406. PubMed ID: 32474109
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with chronic chagas disease and implantable cardioverter-defibrillator.
Pereira FT; Rocha EA; Monteiro Mde P; Neto AC; Daher Ede F; Sobrinho CR; Pires Neto Rda J
Pacing Clin Electrophysiol; 2014 Jun; 37(6):751-6. PubMed ID: 24467488
[TBL] [Abstract][Full Text] [Related]
16. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
[TBL] [Abstract][Full Text] [Related]
17. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
18. Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.
Platonov PG; Haugaa KH; Bundgaard H; Svensson A; Gilljam T; Hansen J; Madsen T; Holst AG; Carlson J; Lie ØH; Kvistholm Jensen M; Edvardsen T; Jensen HK; Svendsen JH
Am J Cardiol; 2019 Apr; 123(7):1156-1162. PubMed ID: 30678832
[TBL] [Abstract][Full Text] [Related]
19. Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients.
Biton Y; Rosero S; Moss AJ; Goldenberg I; Kutyifa V; McNitt S; Polonsky B; Baman JR; Zareba W
Europace; 2019 Feb; 21(2):339-346. PubMed ID: 29947754
[TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
